Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins

Launched by CHARITE UNIVERSITY, BERLIN, GERMANY · Sep 21, 2020

Keywords

ClinConnect Summary

This clinical trial is exploring how different types of protein—specifically, fast-digesting whey protein and slow-digesting casein protein—affect liver fat and sugar control in people with Type 2 Diabetes and non-alcoholic fatty liver disease (NAFLD). Researchers want to find out if one type of protein is more effective than the other in improving these health issues. They will be studying 80 participants over three weeks, measuring changes in liver fat and how the body processes sugar after meals.

To participate, individuals need to be between 18 and 79 years old and have Type 2 Diabetes along with NAFLD. There are some health conditions and medications that could exclude someone from joining, like having Type 1 Diabetes or certain severe disorders. Participants will undergo various tests before and after the study, including MRI scans and blood tests, to track how their bodies respond to the different proteins. This trial will help us understand the potential benefits of protein types in managing diabetes and liver health.

Gender

ALL

Eligibility criteria

• Subcohort 1 (n=46):
• Inclusion Criteria:
• • healthy glucose levels or T2DM
• • 40-79 years
• • overweight/obesity
• Main Exclusion Criteria:
• • type 1 diabetes, prediabetes
• • currently receiving treatment with insulin
• • lactose intolerance, or food intolerance/allergy to any of the study products
• • severe endocrine, gastrointestinal, metabolic, cardiovascular, pulmonary, inflammatory or psychiatric disorder
• • active or recent relevant cancer
• • intake of glucocorticoids or other medication that influences glucose metabolism
• • pregnancy, breastfeeding
• Subcohort 2 (n=80):
• Inclusion Criteria:
• • T2DM
• • with NAFLD
• • 18-79 years
• Main Exclusion Criteria:
• • type 1 diabetes, prediabetes
• • currently receiving treatment with insulin
• • lactose intolerance, or food intolerance/allergy to any of the study products
• • severe endocrine, gastrointestinal, metabolic, cardiovascular, pulmonary, inflammatory or psychiatric disorder
• • active or recent relevant cancer
• • intake of glucocorticoids or other medication that influences glucose metabolism
• • pregnancy, breastfeeding
• • claustrophobia